Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics (AUTL) announced significant progress on AUTO3, a dual-targeting CAR T cell therapy for diffuse large B cell lymphoma, during the ESMO Virtual Congress 2020. New data from the Phase 1/2 ALEXANDER study reveal a promising 64% complete response rate and a 71% overall response rate in evaluated patients. AUTO3 demonstrated a favorable safety profile, with low rates of neurotoxicity and no serious cytokine release syndrome reported. The results position AUTO3 as a potential best-in-class treatment option, highlighting its durability and efficacy in a patient cohort.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced an upcoming investor conference call to discuss data on its AUTO3 program presented at the ESMO Virtual Congress 2020. Key events include participation in the Wells Fargo Virtual Healthcare Conference on September 9, the H.C. Wainwright & Co conference on September 15, and the Cantor Fitzgerald conference on September 17. A detailed investor call regarding AUTO3 will occur on September 18, with Dr. Christian Itin and the clinical team. For additional details, visit Autolus.
Autolus Therapeutics (NASDAQ: AUTL) announced the initiation of its pivotal Phase 1b/2 AUTO1-AL1 study for adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). As of May 13, 2020, AUTO1 demonstrated a favorable safety profile, achieving an 84% MRD-negative complete response (CR) in 19 patients. Notably, event-free survival at 6 months was 62%, with overall survival at 72%. Meanwhile, progress on AUTO3 suggests potential use in outpatient settings. The company will discuss EHA data in a conference call on June 12, 2020.
Autolus Therapeutics plc (Nasdaq: AUTL) has rescheduled its investor conference call to discuss data from the European Hematology Association EHA25 Virtual Congress to June 12, 2020, at 7:30 am EDT. Previously set for June 15, the call will feature Dr. Christian Itin and the AUTO1 and AUTO3 clinical teams discussing CAR T cell therapies targeting adult Acute Lymphocytic Leukemia and relapsed/refractory Diffuse Large B Cell Lymphoma. Investors can join via a dial-in or webcast, with a replay available afterward.
Autolus Therapeutics (AUTL) has announced its Annual General Meeting (AGM) scheduled for June 18, 2020, at its headquarters in White City. Due to UK government Stay at Home Measures amid the coronavirus pandemic, only two shareholders will attend in person, and the meeting will not have a webcast. Shareholders are urged to vote via proxy ahead of the meeting, as in-person voting is not permitted this year. Results of the poll votes will be communicated through a subsequent press release. Autolus focuses on developing innovative programmed T cell therapies for cancer treatment.
Autolus Therapeutics plc (Nasdaq: AUTL) announced new preclinical data on its programmed T cell therapies at the AACR Virtual Annual Meeting II, scheduled for June 22-24, 2020. Key presentations include AUTO5 targeting T cell lymphoma, AUTO6NG for small cell lung cancer, and AUTO7 for advanced prostate cancer. Oral and poster presentations will showcase the advancements and efficacy of these therapies. A conference call to discuss the findings will be held on June 25, 2020, at 8:30 am EDT. These developments highlight Autolus's commitment to innovative cancer treatments.
Summary not available.